Giropharm Competitors

Founded in 1969, Cegedim is an innovative technology and services company in the field of digital data flow management for healthcare ecosystems and B2B, and a business software publisher for healthcare and insurance professionals. Cegedim employs 6,500 people in more than 10 countries and generated revenue of €649.2 million in 2025. Cegedim SA is listed in Paris (EURONEXT: CGM). To learn more, please visit: www.cegedim.com And follow Cegedim on X: https://bit.ly/3HCgucL & Facebook: https://bit.ly/42i5fji & Instagram: https://bit.ly/3vWKBt7

Unither Pharmaceuticals, with 8 manufacturing plants (France, USA, Brazil and China) 4 commercial offices and 1 R&D platform, is the worldwide leader in sterile unit-doses contract manufacturing. Unither Pharmaceuticals manufactures several product lines, using highly innovative and competitive niche technologies such as: Liquid Stick-Pack, Sterile unit-dose (Blow Fill & Seal Technology), Multidoses with and without preservative, Pharmaceuticals bottles, Suppositories and Pessaries, etc. Our products are sold in more than 100 countries for an annual turnover of 371 million euros. Our vision is to be recognized for making affordable healthcare solutions that improve and simplify patients’ lives for as many people as possible. Our mission is to deliver innovative, competitive and sustainable solutions to our customers: pharmaceutical companies. Our promise is to consider patients’ needs in order to make successful products for our pharmaceutical customers.

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinical Trial Services Clinigen is the global market leader in the specialist supply and management of quality-assured comparator medicines and services to clinical trials and Investigator Initiated Trials. Unlicensed Medicines Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages early access programmes to innovative new medicines and provides ‘on demand’ access globally to medicines which remain unlicensed at the point of care. Commercial Medicines Clinigen acquires global rights to niche hospital only and critical care products, revitalising these assets around the world and returning them back to sustained growth. It also provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Group also has an ‘unlicensed to licensed’ strategy, where it looks to take unlicensed medicines with commercial potential and licence them, helping to address unmet medical need and allowing the Group to capitalise on its market-leading positions. Clinigen supplies to more than 130 countries across the world from its global offices in the United Kingdom, United States, Japan, Singapore, Australia, New Zealand and South Africa.